Asset sale Pending
SERB Pharmaceuticals acquisition of Exclusive development and commercialisation rights to Idefirix in Europe and MENA
€115m consideration
Announced 19 May 2026
Advisers
Exclusive development and commercialisation rights to Idefirix in Europe and MENA
Target
Not disclosed
SERB Pharmaceuticals
Acquirer
- Legal adviser
- Target
- Exclusive development and commercialisation rights to Idefirix in Europe and MENA
- Acquirer
- SERB Pharmaceuticals
- Seller
- Hansa Biopharma AB
- Buyer based in
- France
- Seller based in
- Sweden (unverified)
- Sector
- Pharma
- Tags
- Pharma, Rare Disease
Similar deals
- LEO Pharma acquisition of global rights for MT-7117 (dersimelagon) Aug 2026 · US$435m · Pharma
- ANI Pharmaceuticals acquisition of Egetis 2026 · US$560m · Pharma
- Chiesi Group acquisition of KalVista Pharmaceuticals Apr 2026 · US$1.9bn · Pharma
- Neurocrine Biosciences acquisition of Soleno Therapeutics Apr 2026 · US$2.9bn · Biotech
- Angelini Pharma S.p.A. acquisition of Catalyst Pharmaceuticals May 2026 · US$4.1bn · Pharma
Sources
- 19 May 2026 Freshfields Advises SERB Pharmaceuticals on acquisition of European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million freshfields.com
- 22 May 2026 Mayer Brown advises SERB Pharmaceuticals on the agreement entered into with Hansa Biopharma AB to acquire European and MENA rights to Idefirix®(imlifidase) mayerbrown.com
